In this study, Notch 3 overexpression increased the ovarian cancer side population, while treatment with a Notch 3 inhibitor depleted the ovarian CSC/TIC population and increased sensitivity to platinum. The gene discussed is NOTCH3; the disease is ovarian carcinoma.